These drugs are called disease-modifying antirheumatic drugs (DMARDs), and they are an important part of an overall treatment plan. Disease-modifying drugs act on the immune system to slow the progression of rheumatoid arthritis. This is why they are called "disease-modifying." Many different drugs can be used as DMARDs in the treatment of RA, but some are used more often than others. Plaquenil a adderall Plaquenil retinal screening interval Plaquenil sun pharmaceuticals Pics of corneal chloroquine toxicity Apr 14, 2017 The study was a follow-up to the Rheumatoid Arthritis Comparison of Active Therapies RACAT trial, a double-blinded trial that assigned patients with active rheumatoid arthritis RA who were on methotrexate mean dose of 19.6 mg per week to receive additional treatment of sulfasalazine and hydroxychloroquine as triple therapy, or etanercept. If one or two medications are not enough, doctors can turn to triple therapy. The most common combination is methotrexate, sulfasalazine and hydroxychloroquine. Research shows that in some cases, using three conventional DMARDs together is just as effective as using a DMARD in combination with a biologic drug. Orencia may be used as monotherapy or concomitantly with methotrexate MTX. • Treatment of adult patients with active psoriatic arthritis PsA Limitations of use Orencia should not be administered concomitantly with TNF antagonists. Orencia is not recommended for use concomitantly with other biologic RA therapy, such as anakinra. They are not as powerful as other DMARDs, but they usually cause fewer side effects. Hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine) are used for mild rheumatoid arthritis. Abatacept sulfasalazine hydroxychloroquine triple therapy DMARDs for Treating Rheumatoid Arthritis, DMARDs Arthritis Foundation Plaquenil doses lupusWhat chloroquinePlaquenil inflammatory arthritisTaking too much hydroxychloroquine Apr 04, 2016 Triple therapy, which consists of three well-established DMARDs sulfasalazine a sulfa drug, hydroxychloroquine Plaquenil, and methotrexate, was shown to have comparable benefits to a combination biologic/methotrexate therapy. The Good News - Bad News About Triple Therapy.. Clinical Policy Abatacept Orencia. Health and Community Services ABATACEPT ORENCIA 250 MG VIAL.. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis Swefot trial 1-year results of a randomised trial Conclusions Triple therapy methotrexate plus sulfasalazine plus hydroxychloroquine and most regimens combining biologic DMARDs with methotrexate were effective in controlling disease activity, and all were generally well tolerated in both methotrexate naive and methotrexate exposed patients. The first-line agent should be metho- trexate MTX, with leflunomide, sulfasalazine, or hydroxychloroquine as an alternative. If monotherapy is not sufficient to reach the target goal, triple therapy or MTX plus a tumor necrosis factor-alpha TNF-alpha inhibitor should be considered.